Pfizer Secures Unconditional EU Antitrust Approval For $43B Seagen Deal
Portfolio Pulse from Benzinga Newsdesk
Pfizer has received unconditional EU antitrust approval for its $43 billion acquisition of Seagen. This deal is expected to strengthen Pfizer's oncology portfolio.
October 19, 2023 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The approval of Pfizer's acquisition of Seagen by the EU antitrust could potentially impact the ETF VGK, which includes European stocks.
The approval of Pfizer's acquisition of Seagen by the EU antitrust could potentially impact the ETF VGK, which includes European stocks. However, the direct impact on VGK is uncertain as it depends on the weightage of Pfizer and Seagen in the ETF.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Pfizer's acquisition of Seagen has been approved by the EU antitrust, which could strengthen its oncology portfolio.
The approval of the acquisition by the EU antitrust removes a significant hurdle for Pfizer. This could potentially strengthen Pfizer's oncology portfolio, which may positively impact its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Seagen's acquisition by Pfizer has been approved by the EU antitrust, which could lead to a change in its stock price.
The approval of the acquisition by the EU antitrust removes a significant hurdle for Seagen. This could potentially lead to a change in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100